Literature DB >> 20337923

Total and cause-specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in northern Norway.

M G Kristiansen1, M-L Løchen, T J Gutteberg, L Mortensen, B O Eriksen, J Florholmen.   

Abstract

Knowledge of the natural course and especially the total and cause-specific mortality of community-acquired chronic HCV infection is limited. The aims of our study were to determine the total and cause-specific mortality in patients infected with chronic hepatitis C in a community-based setting in northern Norway. This prospective cohort study included 1010 HCV-positive patients diagnosed with recombinant immunoblot assay between 1 January 1990 and 1 January 2000, with a median observation time from diagnosis to follow-up of 7 years. Data were collected from medical records in the period between 1 January 2004 and 30 June 2006. Time and cause of death were ascertained from the Norwegian Causes of Death Register. Age-adjusted death rates and standardised mortality ratios (SMRs) were compared with those of the general Norwegian population. In total, 122 deaths were recorded. The Kaplan-Meier estimate of survival was 88% at 14 years. The SMR in the cohort relative to the general population was 6.66. Most of the excess deaths in both genders were because of liver-related causes, those associated with a drug-using lifestyle and suicide. The statistically significant increase in SMRs ranged from 4.2 for death by cancer in women to 64.6 for liver disease in women. There was no statistically significant increase in SMRs from cardiovascular disease in either gender or from cancer in men. In conclusion, our study shows that the death rate in patients infected with hepatitis C is 6.66 times higher than in the general Norwegian population.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 20337923     DOI: 10.1111/j.1365-2893.2010.01290.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

Review 1.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Mortality among British Columbians testing for hepatitis C antibody.

Authors:  Amanda Yu; John J Spinelli; Darrel A Cook; Jane A Buxton; Mel Krajden
Journal:  BMC Public Health       Date:  2013-04-02       Impact factor: 3.295

Review 3.  Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment.

Authors:  Laura A Lucaciu; Dan L Dumitrascu
Journal:  Ann Gastroenterol       Date:  2015 Oct-Dec

Review 4.  Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review.

Authors:  Ahmed Babiker; Jean Jeudy; Seth Kligerman; Miriam Khambaty; Anoop Shah; Shashwatee Bagchi
Journal:  J Clin Transl Hepatol       Date:  2017-08-31

5.  Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017).

Authors:  Alaa Badawi; Giancarlo Di Giuseppe; Paul Arora
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

6.  Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study.

Authors:  Hélio Ranes de Menezes Filho; Ana Luiza de Souza Bierrenbach; Maria Ligia Damato Capuani; Alfredo Mendrone; Adele Schwartz Benzaken; Soraia Mafra Machado; Marielena Vogel Saivish; Ester Cerdeira Sabino; Steven Sol Witkin; Maria Cássia Mendes-Corrêa
Journal:  PLoS One       Date:  2019-12-19       Impact factor: 3.240

7.  Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy.

Authors:  Pierluca Piselli; Diego Serraino; Mario Fusco; Enrico Girardi; Angelo Pirozzi; Federica Toffolutti; Claudia Cimaglia; Martina Taborelli
Journal:  BMC Infect Dis       Date:  2021-07-08       Impact factor: 3.090

8.  Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.

Authors:  Kuan Ken Lee; Dominik Stelzle; Rong Bing; Mohamed Anwar; Fiona Strachan; Sophia Bashir; David E Newby; Jasmit S Shah; Michael H Chung; Gerald S Bloomfield; Chris T Longenecker; Shashwatee Bagchi; Shyamasundaran Kottilil; Sarah Blach; Homie Razavi; Peter R Mills; Nicholas L Mills; David A McAllister; Anoop S V Shah
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-07-31

9.  Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection.

Authors:  Alaa Badawi; Giancarlo Di Giuseppe; Alind Gupta; Abbey Poirier; Paul Arora
Journal:  BMJ Open       Date:  2020-05-05       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.